Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00022633 · OUTCOME

Overall Survival (OS) in Patients Aged 70 Years and Older

S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract · Source last updated 2016-08-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
0-5 years

What was measured

Measured from date of registration to date of death due to any cause.

Analysis population: Eligible patients aged 70 years and older who had received any treatment were included in the analysis. Patients aged 60 years or younger who served as a younger reference group for the pharmacokinetic study were excluded from analysis.

Groups in this outcome

Paclitaxel + Gemcitabine (Elderly Cohort: Age >= 70)

Patients received 1000 mg /m\^2 of gemcitabine on Day 1 and 8 and 175 mg/m\^2 of paclitaxel on Day 1 intravenously every 21 days for 6 cycles ( 1 cycle = 21 days)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Paclitaxel + Gemcitabine (Elderly Cohort: Age >= 70)51

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Paclitaxel + Gemcitabine (Elderly Cohort: Age >= 70)11Not reported813Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        8
        upper Limit
        13
        value
        11
denoms
  1. counts
    1. group Id
      OG000
      value
      51
    units
    Participants
description
Measured from date of registration to date of death due to any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients received 1000 mg /m\^2 of gemcitabine on Day 1 and 8 and 175 mg/m\^2 of paclitaxel on Day 1 intravenously every 21 days for 6 cycles ( 1 cycle = 21 days)
    id
    OG000
    title
    Paclitaxel + Gemcitabine (Elderly Cohort: Age >= 70)
param Type
MEDIAN
population Description
Eligible patients aged 70 years and older who had received any treatment were included in the analysis. Patients aged 60 years or younger who served as a younger reference group for the pharmacokinetic study were excluded from analysis.
reporting Status
POSTED
time Frame
0-5 years
title
Overall Survival (OS) in Patients Aged 70 Years and Older
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice